Here’s How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 5 years by 4.1% on an annualized basis…
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 1.63% on an annualized basis…
Behind the Scenes of Alnylam Pharmaceuticals’s Latest Options Trends
Financial giants have made a conspicuous bullish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam…
(ALNY) – Analyzing Alnylam Pharmaceuticals’s Short Interest
Alnylam Pharmaceuticals’s (NYSE:ALNY) short percent of float has risen 4.82% since its last report. The company recently reported…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Alnylam Pharmaceuticals Reiterats 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.4B-$1.5B
2024 Financial GuidanceFull year 2024 financial guidance is reiterated as follows:Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 $1,400 million - $1,500 millionNet Product Revenue Growth
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals’s (NYSE:ALNY) short percent of float has fallen 9.57% since its last report. The company recently reported…
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Analysts Express Confidence in Alnylam’s Hypertension Drug Despite Mixed Trial Data
The latest findings from Alnylam Pharmaceuticals' KARDIA-2 Phase 2 study are on zilebesiran's efficacy and safety in treating hypertension. Results show significant reductions in systolic blood pressure with standard-of-care antihypertensives.
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 1.97% on an annualized basis…